Artivion (AORT)
(Real Time Quote from BATS)
$25.54 USD
+0.39 (1.55%)
Updated Aug 8, 2024 09:56 AM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AORT 25.54 +0.39(1.55%)
Will AORT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AORT
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
AORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
Other News for AORT
Artivion to Participate in Upcoming Investor Conferences
Lake Street Sticks to Their Buy Rating for Artivion (AORT)
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
Next Century Growth Investors Q2 2024 Commentary
Artivion Amends Agreements with Endospan